[go: up one dir, main page]

ES2171410T3 - Vacunas antitumorales. - Google Patents

Vacunas antitumorales.

Info

Publication number
ES2171410T3
ES2171410T3 ES93900706T ES93900706T ES2171410T3 ES 2171410 T3 ES2171410 T3 ES 2171410T3 ES 93900706 T ES93900706 T ES 93900706T ES 93900706 T ES93900706 T ES 93900706T ES 2171410 T3 ES2171410 T3 ES 2171410T3
Authority
ES
Spain
Prior art keywords
tumors
antigens
those
pancreas
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93900706T
Other languages
English (en)
Inventor
Lynn E Spitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenner Technologies
Original Assignee
Jenner Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenner Technologies filed Critical Jenner Technologies
Application granted granted Critical
Publication of ES2171410T3 publication Critical patent/ES2171410T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTIGENOS ASOCIADOS A TUMOR QUE CARACTERIZAN LOS TUMORES DE LOS TIPOS HISTOLOGICOS DADOS SON EJEMPLARIZADOS POR EL CO-029, QUE SE ASOCIA CON TUMORES DEL APARATO GASTROINTESTINAL, COLON RECTO Y PANCREAS, Y POR EL GA-733-2, QUE SE ASOCIA CON TUMORES DEL APARATO GASTROINTESTINAL, PROSTATA, CUELLO, OVARIOS, VEJIGA, PULMON, PECHO, COLON RECTO Y PANCREAS. ESOS ANTIGENOS, QUE SON EXTENSAMENTE COMPARTIDOS POR ESOS TUMORES, PUEDEN SER PREPARADOS SINTETICAMENTE, INDEPENDIENTES DEL TUMOR MISMO. ESOS ANTIGENOS PREPARADOS INDEPENDIENTEMENTE SON UTILES COMO INGREDIENTES ACTIVOS EN COMPOSICIONES QUE SUMINISTRAN PROTOCOLOS TERAPEUTICOS A SUJETOS QUE PORTAN TALES TUMORES O ESTAN EN RIESGO DE TALES TUMORES. LAS COMPOSICIONES DE LA VACUNA DEL INVENTO HAN AUMENTADO LA ANTIGENITICIDAD POR VIRTUD DE LA ENCAPSULACION DE ESOS ANTIGENOS EN LIPOSOMAS O CONEXIONES COVALENTES DE LOS ANTIGENOS CON LIPOSOMAS.
ES93900706T 1991-11-26 1992-11-25 Vacunas antitumorales. Expired - Lifetime ES2171410T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80047491A 1991-11-26 1991-11-26

Publications (1)

Publication Number Publication Date
ES2171410T3 true ES2171410T3 (es) 2002-09-16

Family

ID=25178488

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93900706T Expired - Lifetime ES2171410T3 (es) 1991-11-26 1992-11-25 Vacunas antitumorales.

Country Status (11)

Country Link
US (1) US5738867A (es)
EP (1) EP0614355B1 (es)
JP (2) JPH07501548A (es)
AT (1) ATE212540T1 (es)
AU (1) AU675215B2 (es)
CA (1) CA2123696C (es)
DE (1) DE69232395T2 (es)
DK (1) DK0614355T3 (es)
ES (1) ES2171410T3 (es)
PT (1) PT614355E (es)
WO (1) WO1993010763A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
FR2716373B1 (fr) * 1994-02-23 1996-05-03 Pasteur Institut Liposomes, et leur utilisation pour l'obtention de vaccins.
US6942862B2 (en) 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AU2003251679A1 (en) * 2002-08-07 2004-02-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Rhesus epithelial cell adhesion molecule, nucleic acid encoding the same, and uses thereof
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
WO2006050116A1 (en) * 2004-11-02 2006-05-11 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
CA2652434A1 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized proteins that target ep-cam
WO2023122075A1 (en) * 2021-12-20 2023-06-29 Ohio State Innovation Foundation Compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165238A (en) * 1980-03-12 1984-04-10 Demetrios P. Papahadjopoulos Activated liposomes and method
US4343895A (en) * 1980-05-23 1982-08-10 Stephen Sugaar Encapsulated antigenic tumor specific substances and methods for detecting cancer using said substances
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JPH02188532A (ja) * 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン

Also Published As

Publication number Publication date
EP0614355B1 (en) 2002-01-30
EP0614355A4 (en) 1997-10-01
DE69232395T2 (de) 2002-11-14
PT614355E (pt) 2002-07-31
CA2123696C (en) 2002-07-02
WO1993010763A1 (en) 1993-06-10
ATE212540T1 (de) 2002-02-15
JP2002104993A (ja) 2002-04-10
AU675215B2 (en) 1997-01-30
AU3228393A (en) 1993-06-28
JPH07501548A (ja) 1995-02-16
EP0614355A1 (en) 1994-09-14
CA2123696A1 (en) 1993-06-10
DK0614355T3 (da) 2002-03-11
DE69232395D1 (de) 2002-03-14
US5738867A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
ES2171410T3 (es) Vacunas antitumorales.
MXPA03001634A (es) Polipeptido tumoral cripto.
Chen et al. Tumor-derived extracellular vesicles: Regulators of tumor microenvironment and the enlightenment in tumor therapy
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
BR0115162A (pt) Tratamentos antitumorais eficazes
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
BRPI0418157A (pt) terapêutica de tumores alogênicos
ES2177636T3 (es) Utilizacion del agua empobrecida en deuterio en la preparacion de cosmeticos.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
AR034059A1 (es) Producto que comprende mikanolido, dihidromikanolido o analogos de los mismos en combinacion con otro agente anticanceroso para uso terapeutico en el tratamiento del cancer
SI1433478T1 (sl) Farmacevtske formulacije za tiroidne hormone in postopki za njihovo pripravo
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
EA200300427A1 (ru) Противоопухолевая терапия, включающая производные дистамицина
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
ES2188802T3 (es) Vectores viricos de replicacion condicional y su uso.
DK225689A (da) Anvendelse af metalloporphyriner til modvirkning af den toksiske virkning af tumorterapi
ES2164011B1 (es) Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
ES2165856T3 (es) Tratamiento de estados fisiologicos con un liquido de perfluorocarbono desgasificado.
ES2187500T3 (es) Uso de topotecano en el tratamiento del carcinoma pulmonar no de celulas pequeñas.
ES2594490B1 (es) Nueva plantilla para calzado
IT1204764B (it) Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici
ES2211374T1 (es) Dosificacion metronomica de taxanos para inhibir el crecimiento tumoral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 614355

Country of ref document: ES